Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration.

Background: Limited data exist for dosing of zanamivir in the setting of CVVH in the intensive care unit (ICU). Our objective is to report the pharmacokinetics and sieving coefficient (S) of zanamivir in patients receiving continuous venovenous hemofiltration (CVVH).

Methods: In this prospective observational study, patients of ≥18 years admitted to the ICU with a life-threatening Influenza A or B infection, treated with zanamivir i.